Riptide Aspiration System (React 71 Catheter)

K182101 · Micro Therapeutics, Inc. d/b/a ev3 Neurovascular · NRY · Nov 14, 2018 · Cardiovascular

Device Facts

• Record ID: K182101
• Device Name: Riptide Aspiration System (React 71 Catheter)
• Applicant: Micro Therapeutics, Inc. d/b/a ev3 Neurovascular
• Product Code: NRY · Cardiovascular
• Decision Date: Nov 14, 2018
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 870.1250
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Riptide™ Aspiration System is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral - M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.

Device Story

Riptide™ Aspiration System (React™ 71 Catheter) is a single-lumen, variable-stiffness composite catheter; nitinol structure with polymer jacket; PTFE/Engage liner; radiopaque platinum-iridium markerband. Used in clinical settings by physicians to treat acute ischemic stroke. Device is navigated through vasculature to site of occlusion; aspiration is applied to remove thrombus. Output is revascularization of occluded intracranial vessels. Benefits include restoration of blood flow in stroke patients. Operates via mechanical aspiration; no software or AI components.

Clinical Evidence

No clinical data. Substantial equivalence supported by non-clinical bench testing (biocompatibility per ISO 10993-1, mechanical performance, sterility, packaging) and GLP animal studies (porcine model) comparing safety, efficacy, and usability against the Penumbra System® (ACE 68).

Technological Characteristics

Single-lumen composite catheter; nitinol braid/coil reinforcement; PTFE/Engage liner; polyamide/polyolefin/polyurethane extrusions; platinum-iridium markerband. Dimensions: 0.071" ID, 0.0855" max OD. Sterilization: Ethylene Oxide (EO). Single-use, disposable. No software or electronic components.

Indications for Use

Indicated for patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (internal carotid, M1/M2 middle cerebral, basilar, vertebral arteries) within 8 hours of symptom onset. Candidates include those ineligible for or failing IV t-PA therapy.

Regulatory Classification

Identification

A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.

Predicate Devices

• Penumbra System® (ACE 68 Reperfusion Catheter) (K161064)
• Riptide™ Aspiration System (React™ 68 Catheter) (K180705)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters 'FDA' in a blue square, followed by the words 'U.S. FOOD & DRUG ADMINISTRATION' in blue text.

November 14, 2018

Micro Therapeutics, Inc. d/b/a ev3 Neurovascular Rvan Kennev Senior Regulatory Affairs Specialist 9775 Toledo Way Irvine, California 92618

Re: K182101

Trade/Device Name: Riptide™ Aspiration System (React™ 71 Catheter) Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous Catheter Regulatory Class: Class II Product Code: NRY Dated: October 12, 2018 Received: October 15, 2018

Dear Ryan Kenney:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

{1}------------------------------------------------

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803). please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

for

Xiaolin Zheng-S

Carlos L. Peña, PhD, MS Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K182101

Device Name RiptideTM Aspiration System (React™ 71 Catheter)

#### Indications for Use (Describe)

The Riptide™ Aspiration System is intended for use in the revascularization of patients with acute iscoke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral - M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.

| Type of Use (Select one or both, as applicable) |
|------------------------------------------------------------------------------------------------------------------------------|
| <div style="display:flex; align-items:center;"><span>☑</span><span>Prescription Use (Part 21 CFR 801 Subpart D)</span></div> |
| <div style="display:flex; align-items:center;"><span>☐</span><span>Over-The-Counter Use (21 CFR 801 Subpart C)</span></div> |

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

## 510(k) Summary: K182101

| 510(k) Owner: | Micro Therapeutics, Inc. d/b/a ev3 Neurovascular<br>9775 Toledo Way<br>Irvine, CA 92618<br>Establishment Registration No.: 2029214 |
|---------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Ryan Kenney<br>Senior Regulatory Affairs Specialist<br>Telephone: [phone]<br>Email: [e-mail] |
| Date Summary<br>Prepared: | October 12, 2018 |
| Trade Name of<br>Device: | Riptide™ Aspiration System (React™ 71 Catheter) |
| Common Name of<br>Device: | Catheter, Thrombus Retriever |
| Review Panel: | Neurology |
| Product Code: | NRY |
| Regulation Number: | 21 CFR 870.1250 |
| Regulation Name: | Percutaneous Catheter |
| Device Classification: | Class II |
| Predicate Device: | Penumbra System® (ACE 68 Reperfusion Catheter)<br>510(k)#: K161064 |
| Additional Predicate<br>Device: | Riptide™ Aspiration System (React™ 68 Catheter)<br>510(k)#: K180705 |

## Device Description:

The React™ 71 Catheter is a single lumen, flexible, variable stiffness composite catheter with a nitinol structure that is jacketed with a durable polymer outer layer. A lubricious, polytetrafluoroethylene and Engage liner is used to create a structure that has both proximal stiffness and distal flexibility. The React™ 71 Catheter is also designed with an encapsulated radiopaque distal platinum-iridium markerband which is used for visualization under fluoroscopy. The React™ 71 Catheter is introduced into the vasculature through the split y-introducer sheath.

The proximal end of the React™ 71 Catheter is designed with a thermoplastic elastomer strain relief and a clear hub. The distal end of the React™ 71 Catheter is designed with a hydrophilic coating. The React™ 71 Catheter is navigated to the intended treatment site and positioned proximal to the site of occlusion.

### Indications for Use:

The Riptide™ Aspiration System is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral - M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.

{4}------------------------------------------------

| | Penumbra System®<br>(ACE 68 Reperfusion Catheter)<br>(K161064) | Riptide™ Aspiration System<br>(React™ 68 Catheter)<br>(K180705) | Riptide™ Aspiration System<br>(React™ 71 Catheter)<br>(K182101) |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| Indication for Use (IFU)<br>Statement | The Penumbra System® is<br>intended for use in the<br>revascularization of patients with<br>acute ischemic stroke secondary to<br>intracranial large vessel occlusive<br>disease (within the internal carotid,<br>middle cerebral – M1 and M2<br>segments, basilar, and vertebral<br>arteries) within 8 hours of<br>symptom onset. | The Riptide™ Aspiration<br>System is intended for use in<br>the revascularization of<br>patients with acute ischemic<br>stroke secondary to<br>intracranial large vessel<br>occlusive disease (within the<br>internal carotid, middle<br>cerebral - M1 and M2<br>segments, basilar, and<br>vertebral arteries) within 8<br>hours of symptom onset.<br>Patients who are ineligible for<br>intravenous tissue<br>plasminogen activator (IV t-<br>PA) or who fail IV t-PA<br>therapy are candidates for<br>treatment. | Same as K180705 |
| Materials | | | |
| Proximal Hub | Grilamid™ | Trogamid® | Same as K180705 |
| Strain Relief<br>(Hub Sleeve) | Grilamid™ | DynaFlex® | Same as K180705 |
| Strain Relief | 304 Stainless Steel | N/A | Same as K180705 |
| Inner Diameter Band | Polyolefin, PET Yellow<br>(Black Ink) | N/A | Same as K180705 |
| Liner | PTFE | Same as K161064 | Polyolefin,<br>PTFE |
| Braid Reinforcement | N/A | Nitinol | Same as K180705 |
| Coil Reinforcement | 304V Stainless Steel<br>Nickel (55%)/Titanium (45%) | Nitinol | Same as K180705 |
| | Penumbra System®<br>(ACE 68 Reperfusion Catheter)<br>(K161064) | Riptide™ Aspiration System<br>(React™ 68 Catheter)<br>(K180705) | Riptide™ Aspiration System<br>(React™ 71 Catheter)<br>(K182101) |
| Proximal Extrusions | Vestamid®<br>Pebax® 72D | Grilamid™<br>Pebax® 45D<br>Pebax® 55D<br>Pebax® 63D<br>Pebax® 72D | Polyamide<br>Polyolefin<br>Polyurethane |
| Distal Extrusions | Pebax® 35D<br>Pebax® 40D<br>Pebax® 55D<br>Pebax® 63D<br>Pellathane® 80A<br>Tecoflex® 80A | Pebax® 25D<br>Pebax® 35D | |
| Extrusion Colorants | Clear/Natural or Purple | Clear/Natural or Green | Same as K180705 |
| Marker Band | Platinum (90% )/<br>Iridium (10%) | Same | Same |
| Coating | SRDX Harmony | Surmodics Serene® | Same as K180705 |
| Dimensions | | | |
| Working Length | 132 cm | Same | Same |
| Proximal Inner Diameter<br>(ID) | 0.068" (Min.) | 0.068" (Min.) | 0.071" |
| Proximal Outer Diameter<br>(OD) | 0.084" (Max.) | 0.083" (Max.) | 0.0855" (Max.) |
| Distal ID | 0.068" (Min.) | 0.068" (Min.) | 0.071" |
| Distal OD | 0.084" (Max.) | 0.083" (Max.) | 0.0855" (Max.) |
| Coating Length | 30cm | 40cm | Same as K180705 |
| Tip Shape | Straight | Same | Same |
| Accessories | | | |
| Peelable Sheath | PTFE | Same | Same |
| | Penumbra System®<br>(ACE 68 Reperfusion Catheter)<br>(K161064) | Riptide™ Aspiration System<br>(React™ 68 Catheter)<br>(K180705) | Riptide™ Aspiration System<br>(React™ 71 Catheter)<br>(K182101) |
| Rotating Hemostasis<br>Valve | Polycarbonate Silicone O-Ring | N/A | Same as K180705 |
| Shaping Mandrel | 0.038" OD Stainless Steel | | Same as K180705 |
| Packaging | | | |
| Carton | SBS Paperboard | | Same as K180705 |
| Packaging Card | Polyethylene | Same | Same as K180705 |
| Packaging Hoop | Polyethylene | Same | Same as K180705 |
| Packaging Tray | Polyethylene<br>Terephthalate<br>Polystrene | N/A | Same as K180705 |
| Pouch | Polyester<br>Polyethylene<br>Tyvek® | Nylon<br>Tyvek® | Same as K180705 |
| Other | | | |
| Shelf Life | 8 Months | 3 Months | Same as K180705 |
| Sterilization | Ethylene Oxide (EO) | Same | Same |
| Use | Single Use, Disposable | Same | Same |

{5}------------------------------------------------

{6}------------------------------------------------

{7}------------------------------------------------

## Biocompatibility:

Biocompatibility was conducted for the React™ 71 Catheter. The React™ 71 Catheter is categorized as a limited exposure (< 24 hours), external communicating circulating blood. The following biocompatibility was conducted for the React™ 71 Catheter:

| Test Description | Results | Conclusions |
|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Cytotoxicity<br>(Elution Method) | The test article extract showed<br>no evidence of causing cell<br>lysis or toxicity and had a<br>Grade 0 (No Reactivity). The<br>test article extract met the<br>requirements of the test since<br>the grade was < Grade 2<br>(Mild Reactivity). | The ReactTM 71 Catheter is<br>considered non-cytotoxic. |
| Sensitization<br>(Guinea Pig Maximization Test) | The test article extracts<br>showed no evidence of<br>causing delayed dermal<br>contact sensitization in the<br>guinea pig. | The ReactTM 71 Catheter does<br>not elicit a sensitization<br>response. |
| Irritation<br>(Intracutaneous Reactivity) | The test article met the<br>requirements of the test since<br>the difference between each<br>test article extract overall<br>mean score and corresponding<br>control extract overall mean<br>score was 0.0 and 0.2 for the<br>Sodium Chloride and Sesame<br>Oil test article extracts,<br>respectively. | The ReactTM 71 Catheter is<br>considered a non-irritant. |
| Acute Systemic Toxicity<br>(Systemic Toxicity) | There was no mortality or<br>evidence of systemic toxicity<br>from the extracts injected into<br>mice. | The ReactTM 71 Catheter does<br>not indicate signs of toxicity. |
| Hemocompatibility<br>(Hemolysis) | The hemolytic index for the<br>test article in direct contact<br>with blood was 0.8%, and the<br>hemolytic index for the test<br>article extract was 0.0%. | The ReactTM 71 Catheter is<br>considered non-hemolytic. |

{8}------------------------------------------------

| Test Description | Results | Conclusions |
|----------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| Hemocompatibility<br>(Complement Activation) | The concentration of SC5b-9<br>in the test article was not<br>statistically higher than the<br>activated normal human serum<br>control or the negative control.<br>The test article was<br>statistically lower than the<br>sponsor provided control<br>article. | The ReactTM 71 Catheter is not<br>considered to be potential<br>activator of the complement<br>system. |
| Hemocompatibility<br>(Thrombogenicity – Canine<br>Model) | The control article was<br>evaluated and determined to<br>have a mean score of 2.0. The<br>test article was evaluated and<br>determined to have a mean<br>score of 1.7 after four (4)<br>hours (±30 minutes) without<br>systemic anticoagulation. | The ReactTM 71 Catheter<br>demonstrates lower<br>thrombogenic potential in<br>arterial vessels compared to<br>the ACE 68 Reperfusion<br>Catheter. |
| Pyrogenicity<br>(Material Mediated) | Not a single animal showed a<br>temperature rise of 0.5°C or<br>more above its baseline<br>temperature. The total rise of<br>the rabbits' temperature during<br>the three (3) hours was 0.0°C. | The ReactTM 71 Catheter is<br>considered non-pyrogenic. |

The React™ 71 Catheter has been evaluated to meet requirements specified in ISO 10993-1.

## Performance Data – Bench:

Non-clinical bench testing was leveraged and conducted to evaluate the performance of the React™ 71 Catheter.

The following non-clinical bench testing was leveraged for the React™ 71 Catheter:

| Test | Test Method Summary | Results |
|--------------------------------|--------------------------------------------------------|-----------------------------------------------------------------------------------------|
| Microbial | | |
| Ethylene Oxide Residual | The ReactTM 71 Catheter was evaluated per ISO 10993-7. | The ReactTM 71 Catheter met the acceptance criteria for ethylene oxide residual. |
| Ethylene Chlorohydrin Residual | The ReactTM 71 Catheter was evaluated per ISO 10993-7. | The ReactTM 71 Catheter met the acceptance criteria for ethylene chlorohydrin residual. |
| Bioburden Recovery | The ReactTM 71 Catheter was evaluated per ISO 11737-1. | The ReactTM 71 Catheter met the acceptance criteria for bioburden recovery. |

{9}------------------------------------------------

| Test | Test Method Summary | Results |
|---------------------|------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Bacterial Endotoxin | The React™ 71 Catheter was<br>evaluated per ANSI/AAMI<br>ST72 and USP <161>. | The React™ 71 Catheter met<br>the acceptance criteria for<br>bacterial endotoxin. |
| Packaging | | |
| Visual Inspection | The React™ 71 Catheter was<br>evaluated per ASTM F1886. | The React™ 71 Catheter met<br>the acceptance criteria for<br>visual inspection. |
| Bubble Leak | The React™ 71 Catheter was<br>evaluated per ASTM F2096. | The React™ 71 Catheter met<br>the acceptance criteria for<br>bubble leak. |
| Seal Strength | The React™ 71 Catheter was<br>evaluated per ASTM F88. | The React™ 71 Catheter met<br>the acceptance criteria for seal<br>strength. |

The following non-clinical bench testing was conducted for the React™ 71 Catheter:

| Test | Test Method Summary | Results |
|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Microbial<br>Bioburden | The React™ 71 Catheter was<br>evaluated per ISO 11737-1. | The React™ 71 Catheter met<br>the acceptance criteria for<br>bioburden. |
| Performance<br>Visual Inspection | The React™ 71 Catheter was<br>inspected under x2.5<br>magnification. | The React™ 71 Catheter met<br>the acceptance criteria for<br>visual inspection. |
| Dimensional Measurements | The proximal ID, distal, ID,<br>proximal OD, distal OD, usable<br>length, total length, coating<br>length, and distal tip length of<br>the React™ 71 Catheter were<br>measured. | The React™ 71 Catheter met<br>the acceptance criteria for<br>dimensional measurements. |
| Tip Buckling | The React™ 71 Catheter was<br>evaluated for the maximum<br>compressive force it can<br>withstand. | The React™ 71 Catheter met<br>the acceptance criteria for tip<br>buckling. |
| Kink Resistance | The React™ 71 Catheter was<br>evaluated for the maximum<br>kink diameter. | The React™ 71 Catheter met<br>the acceptance criteria for kink<br>resistance. |
| Particulate | The React™ 71 Catheter was<br>evaluated per USP <788>. | The React™ 71 Catheter met<br>the acceptance criteria for<br>particulate. |
| Coating Lubricity | The React™ 71 Catheter was<br>evaluated for the average<br>frictional forces. | The React™ 71 Catheter met<br>the acceptance criteria for<br>coating lubricity. |

{10}------------------------------------------------

| Test | Test Method Summary | Results |
|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Tensile Strength | The ReactTM 71 Catheter was evaluated per ISO 10555-1. Annex B. | The ReactTM 71 Catheter met the acceptance criteria for tensile strength at the hub and shaft. |
| Liquid Leak | The ReactTM 71 Catheter was evaluated per ISO 10555-1. Annex C. | The ReactTM 71 Catheter met the acceptance criteria for liquid leak. |
| Corrosion Resistance | The ReactTM 71 Catheter was evaluated per ISO 10555-1. Annex A. | The ReactTM 71 Catheter met the acceptance criteria for corrosion resistance. |
| Hub Aspiration Resistance | The ReactTM 71 Catheter was evaluated per ISO 10555-1. Annex D. | The ReactTM 71 Catheter met the acceptance criteria for hub air aspiration. |
| Radiopacity | The markerband length and wall thickness of the ReactTM 71 Catheter were measured. In addition, radiopacity was confirmed via fluoroscopy. | The ReactTM 71 Catheter met the acceptance criteria for radiopacity. |
| Luer Standards | The ReactTM 71 Catheter was evaluated per ISO 594-1 and ISO 80369-7. | The ReactTM 71 Catheter met the acceptance criteria for luer standards. |
| Torque to Failure | The ReactTM 71 Catheter was evaluated for transmission of proximal torque to the distal tip. | The ReactTM 71 Catheter was able to withstand torsional forces that are typical of clinical use. |
| Dynamic Pressure | The ReactTM 71 Catheter was evaluated for the amount of pressure it can withstand. | The ReactTM 71 Catheter was able to withstand pressures that are typical of clinical use. |
| Coating Integrity | The ReactTM 71 Catheter was evaluated for coating coverage and lubricity. | The ReactTM 71 Catheter remained coated and lubricious. |

In addition, the following non-clinical bench testing was conducted to evaluate the performance of the Riptide™ Aspiration System (React™ 71 Catheter):

| Test | Test Method Summary | Results |
|-----------------|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| Recanalization | The Riptide™ Aspiration<br>System (React™ 71 Catheter)<br>was evaluated for<br>recanalization. | The Riptide™ Aspiration<br>System (React™ 71 Catheter)<br>met the acceptance criteria for<br>recanalization. |
| Vacuum Pressure | The Riptide™ Aspiration<br>System (React™ 71 Catheter)<br>was evaluated for vacuum<br>pressure. | The Riptide™ Aspiration<br>System (React™ 71 Catheter)<br>met the acceptance criteria for<br>vacuum pressure. |

{11}------------------------------------------------

| Test | Test Method Summary | Results |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| Suction Flow Rate | The Riptide™ Aspiration<br>System (React™ 71 Catheter)<br>was evaluated for suction flow<br>rate. | The Riptide™ Aspiration<br>System (React™ 71 Catheter)<br>met the acceptance criteria for<br>suction flow rate. |
| Lumen Collapse | The Riptide™ Aspiration<br>System (React™ 71 Catheter)<br>was evaluated for lumen<br>collapse. | The Riptide™ Aspiration<br>System (React™ 71 Catheter)<br>remained patent. |
| Usability | The Riptide™ Aspiration<br>System (React™ 71 Catheter)<br>and the Penumbra System®<br>(ACE 68 Reperfusion Catheter)<br>were evaluated for<br>maneuverability, flexibility, the<br>ability to engage and apply<br>aspiration, and the ability to<br>safely retrieve clot. | The Riptide™ Aspiration<br>System (React™ 71 Catheter)<br>met the acceptance criteria for<br>usability. |

## Performance Data - Animal:

Non-clinical animal testing was conducted to evaluate the safety, efficacy, and usability of the Riptide™ Aspiration System (React™ 71 Catheter) in comparison to the Penumbra System® (ACE 68 Reperfusion Catheter) at acute and chronic time points in a porcine model, both in the presence and absence of simulated clot. Non-clinical animal testing was conducted in accordance with 21 CFR Part 58 for Good Laboratory Practice (GLP) for Non-Clinical Laboratory Studies.

### Performance Data - Clinical:

Not Applicable. A determination of substantial equivalence is based upon successful completion of nonclinical bench and animal testing.

### Conclusion:

The design modifications incorporated do not alter the fundamental scientific technology or intended use.

Non-clinical bench and animal testing supports a determination that the subject Riptide™ Aspiration System (React™ 71 Catheter) is substantially equivalent to the predicate Penumbra System® (ACE 68 Reperfusion Catheter).